Results 161 to 170 of about 3,287 (210)

Melatonin Protects Against Cyclophosphamide-induced Premature Ovarian Failure in Rats

, 2022
Hongxia Xu, Xiuming Bao, Hanxin Kong, Junya Yang, Yan Li, Zhiwei Sun   +5 more
openalex   +1 more source

Targeting Tumor Dormancy and Recurrence: Molecular Mechanisms and Peptide Therapeutic Delivery

MedComm – Oncology, Volume 5, Issue 1, March 2026.
This review summarizes the molecular mechanisms that regulate tumor dormancy and its role in cancer recurrence, with emphasis on immune evasion, extracellular matrix remodeling, metabolic regulation and angiogenic switching. It further discusses emerging peptide–based therapeutic strategies aimed at detecting, modulating, and eliminating dormant tumor ...
Abdur Raheem Aleem, Atif Ali, Wajid Ali, Yuying Cheng, Zhibin Yan, Chaoyi Xia, Chenguang Liu, Caiyun Fu, Yiren Hu, Xi Wang   +9 more
wiley   +1 more source

Mechanism study on <italic>Er’zhi Tiangui Formula</italic> (二至天癸方) in improving ovarian function in rats with premature ovarian failure [PDF]

Xiaoliang Liu, D. Liu, Fang Lian, Hongyun Wu, Sheng Xiang, Lei Zhang   +5 more
openalex   +1 more source

Aging‐Derived Alterations in Genomic, Immune, and Metabolic Networks: Implications for Cancer Development and Therapy

MedComm – Oncology, Volume 5, Issue 1, March 2026.
Ageing acts as a double‐edged sword in cancer. In the elderly, open chromatin, immunosenescence, and chronic inflammation drive SASP (IL‐6, MMPs), MDSC accumulation and T‐cell suppression, fostering tumor‐promoting microenvironments and limited therapeutic benefit.
Qi Wang, Xue Sun, Xinhao Han, Xingda Zhang, Wenzheng Wang, Hongbin Wang, He Ren, Lina Gu   +7 more
wiley   +1 more source

Multifacet Roles of Cellular Senescence in Cancer: Mechanisms and Therapeutic Implications

MedComm – Oncology, Volume 5, Issue 1, March 2026.
Cellular senescence shapes tumor progression through both antitumor and protumor mechanisms. Senescence triggered by telomere shortening restricts malignant transformation and limits tumor cell proliferation, while the senescence‐associated secretory phenotype (SASP) secretion enhances antitumor immunity by activating cytotoxic T cells.
Huajie Mao, Wanning Liu, Yuanyuan Su, Yuxuan Ma, Xiaodi Zhao, Yuanyuan Lu   +5 more
wiley   +1 more source

Variable expression of the Fragile X Mental Retardation 1 (FMR1) gene in patients with premature ovarian failure syndrome is not dependent on number of (CGG)n triplets in exon 1 [PDF]

, 2011
Julia Schuettler, Zhongying Peng, J. Zimmer, Hans‐Peter Sinn, Cornelia von Hagens, T. Strowitzki, P. H. Vogt   +6 more
openalex   +1 more source

Potential Drivers of Successful Biocontrol: A Perspective on Parasitoids

New Zealand Journal of Zoology, Volume 53, Issue 1, March 2026.
Parasitoids are central to classical biological control, yet predicting their long‐term effectiveness post release remains challenging. In Aotearoa New Zealand, three Microctonus (Hymenoptera: Braconidae) species have been used against pest weevils, but key aspects of their biology remain poorly understood.
Meeran Hussain, Elahe Parvizi, Mark R. McNeill, Ang McGaughran   +3 more
wiley   +1 more source

Carvacrol ameliorates cyclophosphamide-induced rat premature ovarian failure and uterine fibrosis via regulating PI3K/AKT/FOXO3a signaling pathway

El-Gendy, Zeinab A., Soliman, Seham Samir, Aly, Mohamed S., Baraka, Sara M.   +3 more
openalex   +1 more source

Society for Maternal‐Fetal Medicine Consult Series #76: Cancer in pregnancy

Pregnancy, Volume 2, Issue 2, March 2026.
Abstract Approximately one in 1000 pregnancies is complicated by the diagnosis of cancer each year, and the incidence of cancer among reproductive‐age individuals is increasing. Management of a pregnant person with cancer can be complex and warrants a multidisciplinary approach to care.
Society for Maternal‐Fetal Medicine (SMFM), Moti Gulersen, Clarissa Bonanno, Justin S. Brandt, Stephanie Pierce, Elyce H. Cardonick, SMFM Publications Committee   +6 more
wiley   +1 more source

Drug Delivery Systems for Resiquimod to Control Myeloid‐Derived Suppressor Cells in Cancer Immunotherapy

WIREs Nanomedicine and Nanobiotechnology, Volume 18, Issue 2, March/April 2026.
Myeloid‐derived suppressor cells (MDSCs) are key contributors to cancer immunotherapy failure and major targets in new therapeutic strategies. We highlight therapeutic approaches to counteract their immunosuppressive functions and discuss recent efforts to optimize drug delivery for controlling MDSCs, focusing on resiquimod as a representative drug ...
Yanying He, Yoon Yeo
wiley   +1 more source